Abstract
Background: Despite the progress made in recent years regarding our understanding of the neurobiology of major depressive disorder (MDD), approximately one third of patients remain unresponsive to treatment. Co-prescribing of GABA-ergic drugs (GDs), such as sedative hypnotics, with antidepressants (ADs) is not uncommon, although how they benefit the outcome, if at all, remains controversial. Adequate compliance is central to a positive outcome, although its impact with respect to drug usage patterns has not been considered. The aim of the current study is to establish how the co-prescribing of GDs is associated with altered antidepressant compliance and which antidepressants (ADs) are associated with the worst compliance in combination with GDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
